Ket Plug / ketaminelab.org and buyketaminepowderonline.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
**FDA Warning Letter to Ket Plug / ketaminelab.org and buyketaminepowderonline.com (MARCS-CMS 728919, June 23, 2026)** The FDA Center for Drug Evaluation and Research (CDER) identified that Ket Plug's websites sell unapproved and misbranded ketamine powder in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(d), 301(a), 502, and 505(a)). The agency determined the product qualifies as a drug based on website claims referencing neuroscience research, brain function, and psychiatric applications, and lacks FDA approval or adequate directions for use; the FDA requested cessation of sales to U.S. consumers, citing risks of contamination, counterfeit products, and serious adverse events from unsupervised use.
Argus analysis
# FDA Warning Letter Analysis: Ket Plug / ketaminelab.org
**Company and Violations**
Ket Plug, operating through websites ketaminelab.org and buyketaminepowderonline.com, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on June 23, 2026. The agency found that the company distributed ketamine powder as an unapproved new drug and misbranded product. FDA's review in April 2026 identified website labeling claiming the product was for "neuroscience and brain function research" and "psychiatric and mood disorder research models"—language establishing drug intent despite claims of research-only use.
**Regulatory Citations and Implications**
The violations cite sections 505(a), 301(d), and 502 of the Federal Food, Drug, and Cosmetic Act, along with 21 CFR 201.128 and 201.5. Section 505(a) requires FDA approval before marketing new drugs; the company had no approved application. Section 502(f)(1) prohibits misbranding when labeling lacks adequate directions for safe use by laypersons. Ketamine's toxicity, potential for harmful effects, and method of administration make it inherently a prescription drug requiring professional supervision—conditions the company could not satisfy through internet sales. These violations indicate the product circumvented FDA's safety and efficacy oversight.
**Response Timeline and Compliance Watch**
The company must submit a written response within 15 business days of receipt to FDAAdvisory@fda.hhs.gov, detailing corrective actions and preventative measures. Peers in pharmaceutical distribution should monitor whether Ket Plug ceases U.S. sales or contests the findings. FDA indicated potential seizure, injunction, or import detention for continued violations. The agency also warned it may notify foreign regulatory authorities if the company continues operating from outside the United States, signaling coordinated international enforcement.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Ket Plug / ketaminelab.org and buyketaminepowderonline.com MARCS-CMS 728919 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Ket Plug / ketaminelab.org and buyketaminepowderonline.com United States sale@ketaminelab.org sale@buyketaminepowderonline.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 728919 To Ket Plug: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website www.buyketaminepowderonline.com (redirected from www.ketaminelab.org). Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.buyketaminepowderonline.com introduces into interstate commerce an unapproved and misbranded ketamine drug product, which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. 2 Given the increased interest in the use of ketamine products, the easy availability of unapproved ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. 3 There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.buyketaminepowderonline.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.buyketaminepowderonline.com, FDA Establishment I…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Ket Plug / ketaminelab.org and buyketaminepowderonline.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Ket Plug / ketaminelab.org and buyketaminepowderonline.com as of 2026-07-07. Argus ingests new FDA enforcement records daily.
- What FDA violations was Ket Plug / ketaminelab.org and buyketaminepowderonline.com cited for?
- The FDA Warning Letter to Ket Plug / ketaminelab.org and buyketaminepowderonline.com (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to Ket Plug / ketaminelab.org and buyketaminepowderonline.com?
- FDA issued the letter (MARCS-CMS 728919) on 2026-06-23 and posted it publicly on fda.gov on 2026-07-07.
- Is the FDA warning letter to Ket Plug / ketaminelab.org and buyketaminepowderonline.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ket-plug-ketaminelaborg-and-buyketaminepowderonlinecom-728919-06232026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Ket Plug / ketaminelab.org and buyketaminepowderonline.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ket-plug-ketaminelab-org-and-buyketaminepowderonline-com-2026-06-23-unapproved-d
"Ket Plug / ketaminelab.org and buyketaminepowderonline.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ket-plug-ketaminelab-org-and-buyketaminepowderonline-com-2026-06-23-unapproved-d.
Argus HQ Research. "Ket Plug / ketaminelab.org and buyketaminepowderonline.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ket-plug-ketaminelab-org-and-buyketaminepowderonline-com-2026-06-23-unapproved-d.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ket_plug_ketaminelab_org_and_buyketaminepowderonline_com_2026_06_23_unapproved_d_2026,
title = {Ket Plug / ketaminelab.org and buyketaminepowderonline.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ket-plug-ketaminelab-org-and-buyketaminepowderonline-com-2026-06-23-unapproved-d},
note = {Accessed: July 13, 2026}
}